115931-11-8 Usage
General Description
4,5-Dihydro-7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide is a chemical compound with potential pharmaceutical applications. It is a pyrazolopyrimidine derivative, and its structure consists of a pyrazolo[1,5-a]pyrimidine core with a carboxamide group at the 3-position and a trifluoromethylphenyl group at the 7-position. 4,5-DIHYDRO-7-[3-(TRIFLUOROMETHYL)PHENYL]PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE has been studied for its potential as a kinase inhibitor, particularly in the treatment of cancer and inflammatory diseases. It has shown promise in inhibiting specific kinases involved in cell signaling pathways, making it a potential candidate for targeted therapy. Further research is needed to fully elucidate its pharmacological properties and therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 115931-11-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,9,3 and 1 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 115931-11:
(8*1)+(7*1)+(6*5)+(5*9)+(4*3)+(3*1)+(2*1)+(1*1)=108
108 % 10 = 8
So 115931-11-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H7F3O3/c1-15-8(14)5-2-3-7(13)6(4-5)9(10,11)12/h2-4,13H,1H3
115931-11-8Relevant articles and documents
N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides
-
, (2008/06/13)
Novel N-((dialkylamino)methylene)-substituted- pyrazolo(1,5-a)pyrimidine-3-carboxamide and N-((dialkylamino) )methylene-substituted-4,5-dihydropyrazolo-(1,5-a)-pyrimidine-3-carboxamide compounds are disclosed which are useful as neurotropic and/or anxiolytic and/or anti-hypertensive agents in mammals.
5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders
-
, (2008/06/13)
This disclosure described novel 5-(substituted-amino)-8-(substituted-phenyl)-3H,6H, -1,-4,5a,8a-tetraazaacenaphthylen-3-ones useful for the treatment of cognitive and related neural behavioral disorders in mammals.